Barzolvolimab

Summary

Barzolvolimab (CHEMBL5095266) is a phase-3 clinical-stage antibody targeting KIT; indicated across 2 conditions including eosinophilic esophagitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (KIT)
• Indications: 2 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095266
Name	Barzolvolimab
Type	Antibody
Max phase	3

Also known as: Barzolvolimab, CDX-0159, BARZOLVOLIMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
KIT	KIT proto-oncogene, receptor tyrosine kinase	Binding		0.5%	P10721

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): KIT.

Top Reactome pathways

39 total, by targets touching each:

Pathway	Targets	Genes
PIP3 activates AKT signaling	1	KIT
Developmental Biology	1	KIT
Signaling by SCF-KIT	1	KIT
Regulation of KIT signaling	1	KIT
Signal Transduction	1	KIT
Disease	1	KIT
Negative regulation of the PI3K/AKT network	1	KIT
Generic Transcription Pathway	1	KIT
PI3K/AKT Signaling in Cancer	1	KIT
Constitutive Signaling by Aberrant PI3K in Cancer	1	KIT
Diseases of signal transduction by growth factor receptors and second messengers	1	KIT
RAF/MAP kinase cascade	1	KIT
MAPK family signaling cascades	1	KIT
MAPK1/MAPK3 signaling	1	KIT
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	1	KIT
RNA Polymerase II Transcription	1	KIT
Gene expression (Transcription)	1	KIT
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	1	KIT
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	1	KIT
Intracellular signaling by second messengers	1	KIT
Signaling by Receptor Tyrosine Kinases	1	KIT
Dasatinib-resistant KIT mutants	1	KIT
Imatinib-resistant KIT mutants	1	KIT
KIT mutants bind TKIs	1	KIT
Masitinib-resistant KIT mutants	1	KIT
Nilotinib-resistant KIT mutants	1	KIT
Regorafenib-resistant KIT mutants	1	KIT
Signaling by kinase domain mutants of KIT	1	KIT
Sunitinib-resistant KIT mutants	1	KIT
Signaling by juxtamembrane domain KIT mutants	1	KIT
Sorafenib-resistant KIT mutants	1	KIT
Drug resistance of KIT mutants	1	KIT
Signaling by KIT in disease	1	KIT
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	1	KIT
Signaling by extracellular domain mutants of KIT	1	KIT
MITF-M-regulated melanocyte development	1	KIT
Transcriptional and post-translational regulation of MITF-M expression and activity	1	KIT
Developmental Lineage of Mammary Gland Luminal Epithelial Cells	1	KIT
Developmental Lineage of Mammary Gland Alveolar Cells	1	KIT

Dominant GO biological processes

GO term	Targets
ovarian follicle development	1
hematopoietic progenitor cell differentiation	1
myeloid progenitor cell differentiation	1
lymphoid progenitor cell differentiation	1
immature B cell differentiation	1
mast cell chemotaxis	1
positive regulation of dendritic cell cytokine production	1
glycosphingolipid metabolic process	1
inflammatory response	1
signal transduction	1
spermatogenesis	1
spermatid development	1
positive regulation of cell population proliferation	1
primordial germ cell migration	1
regulation of cell shape	1

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
eosinophilic esophagitis	2	MONDO:0005361	EFO:0004232

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE2	5
PHASE1	5
PHASE3	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06445023	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06455202	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT07256392	PHASE3	RECRUITING	Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT07266402	PHASE3	RECRUITING	A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
NCT06366750	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Barzolvolimab in Patients With Prurigo Nodularis
NCT06727552	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Barzolvolimab in Patients With Atopic Dermatitis
NCT05368285	PHASE2	COMPLETED	A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
NCT05405660	PHASE2	COMPLETED	A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
NCT05774184	PHASE2	COMPLETED	A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
NCT04146129	PHASE1	COMPLETED	A Phase 1 Study of CDX-0159
NCT04538794	PHASE1	COMPLETED	A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
NCT04548869	PHASE1	COMPLETED	A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
NCT04944862	PHASE1	COMPLETED	A Study of CDX-0159 in Patients With Prurigo Nodularis
NCT05031624	PHASE1	COMPLETED	A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

84 molecules share ≥1 primary target. Top 84 by shared-target count:

Molecule	Source	Status	Shared targets
AVAPRITINIB	ChEMBL + PubChem	Phase 4 (approved)	KIT
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	KIT
GEFITINIB	ChEMBL + PubChem	Phase 4 (approved)	KIT
IMATINIB	ChEMBL + PubChem	Phase 4 (approved)	KIT
PAZOPANIB	ChEMBL + PubChem	Phase 4 (approved)	KIT
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	KIT
AXITINIB	ChEMBL	Phase 4 (approved)	KIT
BOSUTINIB	ChEMBL	Phase 4 (approved)	KIT
BRIGATINIB	ChEMBL	Phase 4 (approved)	KIT
CABOZANTINIB	ChEMBL	Phase 4 (approved)	KIT
CERITINIB	ChEMBL	Phase 4 (approved)	KIT
DASATINIB	ChEMBL	Phase 4 (approved)	KIT
ENTRECTINIB	ChEMBL	Phase 4 (approved)	KIT
ERLOTINIB	ChEMBL	Phase 4 (approved)	KIT
FEDRATINIB	ChEMBL	Phase 4 (approved)	KIT
INFIGRATINIB	ChEMBL	Phase 4 (approved)	KIT
LENVATINIB	ChEMBL	Phase 4 (approved)	KIT
MIDOSTAURIN	ChEMBL	Phase 4 (approved)	KIT
NICLOSAMIDE	ChEMBL	Phase 4 (approved)	KIT
NILOTINIB	ChEMBL	Phase 4 (approved)	KIT
NINTEDANIB	ChEMBL	Phase 4 (approved)	KIT
PEXIDARTINIB	ChEMBL	Phase 4 (approved)	KIT
PONATINIB	ChEMBL	Phase 4 (approved)	KIT
QUIZARTINIB	ChEMBL	Phase 4 (approved)	KIT
RIPRETINIB	ChEMBL	Phase 4 (approved)	KIT
RUXOLITINIB	ChEMBL	Phase 4 (approved)	KIT
SORAFENIB	ChEMBL	Phase 4 (approved)	KIT
SUNITINIB	ChEMBL	Phase 4 (approved)	KIT
TIVOZANIB	ChEMBL	Phase 4 (approved)	KIT
VANDETANIB	ChEMBL	Phase 4 (approved)	KIT
ALVOCIDIB	ChEMBL	Phase 3	KIT
BARASERTIB	ChEMBL	Phase 3	KIT
BEZUCLASTINIB	ChEMBL	Phase 3	KIT
BRIVANIB	ChEMBL	Phase 3	KIT
CANERTINIB	ChEMBL	Phase 3	KIT
CEDIRANIB	ChEMBL	Phase 3	KIT
DOVITINIB	ChEMBL	Phase 3	KIT
ENZASTAURIN	ChEMBL	Phase 3	KIT
FAMITINIB	ChEMBL	Phase 3	KIT
FLUMATINIB	ChEMBL	Phase 3	KIT
LESTAURTINIB	ChEMBL	Phase 3	KIT
LINIFANIB	ChEMBL	Phase 3	KIT
MASITINIB	ChEMBL	Phase 3	KIT
MOTESANIB	ChEMBL	Phase 3	KIT
PIMICOTINIB	ChEMBL	Phase 3	KIT
RUBOXISTAURIN	ChEMBL	Phase 3	KIT
SARACATINIB	ChEMBL	Phase 3	KIT
SEMAXANIB	ChEMBL	Phase 3	KIT
SITRAVATINIB	ChEMBL	Phase 3	KIT
VATALANIB	ChEMBL	Phase 3	KIT
VIMSELTINIB	ChEMBL	Phase 3	KIT
AMUVATINIB	ChEMBL	Phase 2	KIT
BAY-1161909	ChEMBL	Phase 2	KIT
BEMCENTINIB	ChEMBL	Phase 2	KIT
BERZOSERTIB	ChEMBL	Phase 2	KIT
BFH-772	ChEMBL	Phase 2	KIT
BMS-777607	ChEMBL	Phase 2	KIT
CENISERTIB	ChEMBL	Phase 2	KIT
CEP-32496	ChEMBL	Phase 2	KIT
DANUSERTIB	ChEMBL	Phase 2	KIT
DATELLIPTIUM	ChEMBL	Phase 2	KIT
DEFOSBARASERTIB	ChEMBL	Phase 2	KIT
DENFIVONTINIB	ChEMBL	Phase 2	KIT
DORAMAPIMOD	ChEMBL	Phase 2	KIT
EDICOTINIB	ChEMBL	Phase 2	KIT
ELLIPTINIUM	ChEMBL	Phase 2	KIT
ENMD-2076	ChEMBL	Phase 2	KIT
ENRUPATINIB	ChEMBL	Phase 2	KIT
FORETINIB	ChEMBL	Phase 2	KIT
ILORASERTIB	ChEMBL	Phase 2	KIT
LABUXTINIB	ChEMBL	Phase 2	KIT
MILCICLIB	ChEMBL	Phase 2	KIT
R-406	ChEMBL	Phase 2	KIT
RAF-265	ChEMBL	Phase 2	KIT
REBASTINIB	ChEMBL	Phase 2	KIT
RISVODETINIB	ChEMBL	Phase 2	KIT
SOTULETINIB	ChEMBL	Phase 2	KIT
SU-014813	ChEMBL	Phase 2	KIT
TANDUTINIB	ChEMBL	Phase 2	KIT
TELATINIB	ChEMBL	Phase 2	KIT
TOZASERTIB	ChEMBL	Phase 2	KIT
Afatinib	PubChem	Approved	KIT
Idelalisib	PubChem	Approved	KIT
Selumetinib	PubChem	Approved	KIT